| Literature DB >> 34907050 |
Yijie You1, Yunlian Niu2, Fengbing Sun3, Jian Zhang3, Sheng Huang3, Peiyuan Ding1, Xuhui Wang4.
Abstract
BACKGROUND ANDEntities:
Keywords: COVID-19; neurology; neurosurgery; stroke
Mesh:
Year: 2021 PMID: 34907050 PMCID: PMC8671851 DOI: 10.1136/bmjopen-2021-050559
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow chart of study selection process.
Summary of characteristics of included studies
| Author | Study design | Region | Age (years) | Male (%) | Pandemic period | Control period | Total number of intracerebral haemorrhage admissions (pandemic vs control) | Total number of subarachnoid haemorrhage admissions (pandemic vs control) | Total number of haemorrhagic stroke admissions (pandemic vs control) | Total number of stroke admissions (pandemic vs control) |
| Balestrino | Single centre; retrospective | Italy | N/A | N/A | 8 March 2020–2 May 2020 | 8 March 2019–2 May 2019 | N/A | N/A | 20 vs 17 | 124 vs 165 |
| John | Single centre; retrospective | UAE | 48.9 (±14.7) vs 49.3 (±14.1) | 66.7 vs 80.8 | 1 March 2020 –10 May 2020 | 1 March 2019 –10 May 2019 | 24 vs 12 | 13 vs 13 | 42 vs 26 | 210 vs 148 |
| Rameez | Single centre; retrospective | USA | 65.6 vs 72.4 | 61.7 vs 51.3 | 24 March 2020–23 April 2020 | 24 March 2019–23 April 2019 | 9 vs 12 | 0 vs 0 | 9 vs 12 | 47 vs 80 |
| Zini | Single centre; retrospective | Italy | 71.7 (±18) vs 75.2 (±13.8) | 53.8 vs 50.7 | 1 March 2020–30 April 2020 | 1 March 2019–30 April 2019 | 17 vs 21 | N/A | 17 vs 21 | 145 vs 138 |
| Schwarz | Single centre; retrospective | Germany | N/A | N/A | Calendar weeks 1–16 in 2020 | Calendar weeks 1–16 in 2019 | 32 vs 24 | N/A | 32 vs 24 | 286 vs 386 |
| Sarfo | Single centre; retrospective | Ghana | 60.6 (±14.8) vs 59.7 (±15.4) | 57.1 vs 53.4 | 19 January 2020–20 June 2020 | 19 January 2019–20 June 2019 | N/A | N/A | 118 vs 111 | 431 vs 401 |
| Sacco | Multicentre; prospective and retrospective | Italy | 73.5 (±12.9) vs 73.6 (±13.3) | 53 vs 53.4 | 1 March 2020–31 March 2020 | 1 March 2019–31 March 2019 | N/A | N/A | 322 vs 400 | 2379 vs 3145 |
| Roushdy | Single centre; retrospective | Egypt | 63.2 (±12.7) vs 63 (±13.8) | 61.3 vs 57 | 15 February 2020–5 April 2020 | 15 February 2019– | 7 vs 5 | 1 vs 3 | 8 vs 8 | 93 vs 151 |
| Altunisik and Arık | Single centre; retrospective | Turkey | 71.95 (±12.37) vs 70.96 (±13.52) | 61.36 vs 53.93 | 1 April 2020–31 May 2020 | 1 April 2019–31 May 2019 | 3 vs 8 | N/A | 3 vs 8 | 40 vs 72 |
| Luke | Single centre; retrospective | Switzerland | N/A | N/A | 11 March 2020–26 May 2020 | 11 March 2019–26 May 2019 | 26 vs 19 | N/A | 26 vs 19 | 200 vs 223 |
| Thomas | Multicentre; retrospective | Austria | N/A | N/A | 1 March 2020–31 May 2020 | 1 March 2019–31 May 2019 | N/A | N/A | 188 vs 219 | 1014 vs 1185 |
| Abdoreza | Single centre; retrospective | Iran | 69.21 (±13.88) vs 68.74 (±14.49) | 55.17 vs 55.21 | 18 February 2020–18 July 2020 | 18 February 2019–18 July 2019 | 48 vs 50 | N/A | 48 vs 50 | 229 vs 352 |
| Hasan | Single centre; retrospective | Bangladesh | N/A | N/A | 1 April 2020–30 June 2020 | 1 January 2020 –31 March 2020 | 282 vs 449 | 52 vs 182 | 334 vs 631 | 487 vs 907 |
| Robin | Single centre; retrospective | Germany | 77 (64–82) vs 79 (69–85) | 47.6 vs 45.7 | 16 March 2020–12 April 2020 | 16 March 2019–12 April 2019 | 6 vs 6 | N/A | 6 vs 6 | 63 vs 70 |
| Ramírez-Moreno | Multicentre; retrospective | Spain | 70.9 (±2.9) | N/A | 1 January 2020–31 May 2020 | 1 January 2019 –31 May 2019 | N/A | N/A | 44 vs 48 | 273 vs 451 |
| Timo | Single centre; retrospective | Germany | 72.9 (±12.5) vs 72.6 (±13.4) | 46.6 vs 54.3 | March/April 2020 | March/April 2019 | 7 vs 12 | 4 vs 4 | 9 vs 13 | 148 vs 207 |
| Gabriel | Single centre; retrospective | Spain | 68 (53–79) vs 76 (60.2–83) | 51.8 vs 55.4 | 14 March 2020–14 May 2020 | 14 March 2019–14 May 2019 | N/A | N/A | 7 vs 8 | 83 vs 112 |
N/A: No data.
Newcastle–Ottawa quality assessment scale and total score of each study
| Included studies | Newcastle–Ottawa quality assessment scale | Score | |||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Total of number of stars | |
| Balestrino | B | A* | B | A* | A* | A* | A* | A* | 6 |
| John | A* | A* | B | A* | A* | A* | A* | A* | 7 |
| Rameez | B | A* | B | A* | A* | A* | A* | A* | 6 |
| Zini | A* | A* | B | A* | A* | A* | A* | A* | 7 |
| Schwarz | B | A* | B | A* | A* | A* | A* | A* | 6 |
| Sarfo | B | A* | B | A* | A* | A* | A* | A* | 6 |
| Sacco | A* | A* | A* | A* | A** | A* | A* | A* | 9 |
| Roushdy | B | B | B | A* | A* | A* | A* | A* | 5 |
| Altunisik and Arık | A* | A* | B | A* | A* | A* | A* | A* | 7 |
| Luke | A* | A* | B | A* | A* | A* | A* | A* | 7 |
| Thomas | A* | A* | A* | A* | A* | A* | A* | A* | 8 |
| Abdoreza | B | A* | B | A* | A* | A* | A* | A* | 6 |
| Hasan | A* | B | A* | A* | B | A* | A* | A* | 6 |
| Robin | A* | A* | A* | A* | A* | A* | A* | A* | 8 |
| Ramírez-Moreno | A* | A* | B | A* | A* | A* | A* | A* | 7 |
| Timo | A* | A* | A* | A* | A* | A* | A* | A* | 8 |
| Gabriel | A* | A* | A* | A* | A** | A* | A* | A* | 9 |
A*, one star; A**, two stars; B, no star; 1, adequate case definition; 2, representativeness of cases; 3, selection of controls; 4, definition of controls; 5, comparability; 6, ascertainment of exposure; 7, same method; 8, non-response rate.
Figure 2(A) Forest plot showing the HS admission during the pandemic compared with the control period. (B) Forest plot showing the ICH admission during the pandemic compared with the control period. (C) Forest plot showing the SAH admission during the pandemic compared with the control period. HS, haemorrhagic stroke; ICH, intracerebral haemorrhage; SAH, subarachnoid haemorrhage.
Figure 3Funnel plot with the pooled estimate of the fixed-effects model. (A) The funnel plot of HS group. (B) The funnel plot of ICH group. HS, haemorrhagic stroke; ICH, intracerebral haemorrhage